| http://www.w3.org/ns/prov#value | - Meanwhile, the NCIC CTG BR.26 study - in patients with advanced NSCLC previously treated with both chemotherapy and an EGFR inhibitor - did not meet its objective of prolonging overall survival (OS) versus placebo.While we are disappointed in the results, lung cancer is a complex disease, and the use of targeted agents to treat specific patient populations continues to evolve, commented Mace Rot
|
